ProCE Banner Activity

Answering Your Questions: Ocular Toxicity With Antibody–Drug Conjugates

Clinical Thought
How do you monitor for and optimally manage corneal toxicity in patients with cancer receiving antibody–drug conjugates? Expert faculty address frequently asked questions from CCO’s live Webinar, “Mitigation and Management of Ocular Toxicity in Patients Receiving Antibody–Drug Conjugates.”

Released: January 25, 2021

Expiration: January 24, 2022

Share

Faculty

Asim V. Farooq

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Anthony J Perissinotti

Anthony J Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Program Director Disclosure

Program Director

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Asim V. Farooq, MD, has disclosed that he has received consulting fees from GlaxoSmithKline.

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Sanofi, and Takeda; has received funds for research support from Bristol-Myers Squibb, Janssen, and Takeda; and has ownership interest in TG Therapeutics.

Anthony J Perissinotti, PharmD, BCOP

Hematology Clinical Pharmacist Specialist
University of Michigan
Ann Arbor, Michigan

Anthony Perissinotti, PharmD, BCOP, has disclosed that he has received consulting fees from Amgen, Astellas, Celgene/Juno, Coherus BioSciences, and Servier.